Autolus Therapeutics PLC
AUTL1.640USD
-0.090-5.20%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
436.47MMarket Cap
LossP/E TTM
More Details of Autolus Therapeutics PLC Company
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Autolus Therapeutics PLC Info
Ticker SymbolAUTL
Company nameAutolus Therapeutics PLC
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Number of employees647
Security typeDepository Receipt
Fiscal year-endJun 22
AddressThe Mediaworks
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW12 7FP
Phone442038296230
Websitehttps://www.autolus.com/
Ticker SymbolAUTL
IPO dateJun 22, 2018
CEOItin (Christian Martin)
Company Executives of Autolus Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
20.92M
100.00%
United Kingdom
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
10.10%
Clarus Ventures, LLC
7.70%
Syncona Portfolio Ltd
6.25%
Armistice Capital LLC
5.86%
Other
58.54%
Shareholders
Shareholders
Proportion
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
10.10%
Clarus Ventures, LLC
7.70%
Syncona Portfolio Ltd
6.25%
Armistice Capital LLC
5.86%
Other
58.54%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.57%
Investment Advisor
23.48%
Corporation
12.52%
Investment Advisor/Hedge Fund
9.14%
Venture Capital
8.06%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Research Firm
1.83%
Private Equity
1.74%
Other
8.47%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
230
194.47M
90.55%
+128.60K
2025Q3
237
202.34M
94.14%
-20.86M
2025Q2
235
223.88M
91.00%
-2.80M
2025Q1
228
230.12M
90.84%
-11.63M
2024Q4
235
229.60M
92.37%
-10.27M
2024Q3
225
234.01M
89.22%
+30.38M
2024Q2
227
202.70M
79.95%
+2.45M
2024Q1
217
200.05M
58.18%
+45.35M
2023Q4
191
140.21M
76.10%
+4.14M
2023Q3
169
139.76M
70.07%
+377.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
MAK Capital One, LLC
16.96M
6.37%
+16.96M
--
Jun 30, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Jun 30, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Jun 30, 2025
Armistice Capital LLC
12.00M
4.51%
+1.00M
+9.09%
Jun 30, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Polygon Management Ltd.
9.50M
3.57%
+900.00K
+10.47%
Jun 30, 2025
Schroder Investment Management Ltd. (SIM)
3.61M
1.36%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.01%
Tema Oncology ETF
0%
Fidelity Fundamental Small-Mid Cap ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.49%
ALPS Medical Breakthroughs ETF
Proportion0.17%
iShares Health Innovation Active ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
SPDR S&P International Small Cap ETF
Proportion0.01%
Tema Oncology ETF
Proportion0%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Autolus Therapeutics PLC?
The top five shareholders of Autolus Therapeutics PLC are:
Syncona Investment Management Limited holds 30.73M shares, accounting for 11.55% of the total shares.
MAK Capital One, LLC holds 16.96M shares, accounting for 6.37% of the total shares.
Clarus Ventures, LLC holds 20.49M shares, accounting for 7.70% of the total shares.
Syncona Portfolio Ltd holds 16.64M shares, accounting for 6.25% of the total shares.
Armistice Capital LLC holds 12.00M shares, accounting for 4.51% of the total shares.
Syncona Investment Management Limited holds 30.73M shares, accounting for 11.55% of the total shares.
MAK Capital One, LLC holds 16.96M shares, accounting for 6.37% of the total shares.
Clarus Ventures, LLC holds 20.49M shares, accounting for 7.70% of the total shares.
Syncona Portfolio Ltd holds 16.64M shares, accounting for 6.25% of the total shares.
Armistice Capital LLC holds 12.00M shares, accounting for 4.51% of the total shares.
What are the top three shareholder types of Autolus Therapeutics PLC?
The top three shareholder types of Autolus Therapeutics PLC are:
Syncona Investment Management Limited
MAK Capital One, LLC
Clarus Ventures, LLC
Syncona Investment Management Limited
MAK Capital One, LLC
Clarus Ventures, LLC
How many institutions hold shares of Autolus Therapeutics PLC (AUTL)?
As of 2025Q4, 230 institutions hold shares of Autolus Therapeutics PLC, with a combined market value of approximately 194.47M, accounting for 90.55% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.59%.
What is the biggest source of revenue for Autolus Therapeutics PLC?
In FY2025Q2, the -- business generated the highest revenue for Autolus Therapeutics PLC, amounting to -- and accounting for --% of total revenue.
